BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 17065181)

  • 1. Epoprostenol treatment in children with severe pulmonary hypertension.
    Lammers AE; Hislop AA; Flynn Y; Haworth SG
    Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to bosentan in children with pulmonary hypertension.
    Maiya S; Hislop AA; Flynn Y; Haworth SG
    Heart; 2006 May; 92(5):664-70. PubMed ID: 16216850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
    N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
    Sadushi-Koliçi R; Skoro-Sajer N; Zimmer D; Bonderman D; Schemper M; Klepetko W; Glatz J; Jakowitsch J; Lang IM
    J Heart Lung Transplant; 2012 Jul; 31(7):735-43. PubMed ID: 22480725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
    Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
    Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions.
    Scelsi L; Ghio S; Campana C; D'Armini AM; Serio A; Klersy C; Piovella F; Viganò M; Tavazzi L
    Ital Heart J; 2004 Aug; 5(8):618-23. PubMed ID: 15554033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy].
    Uchi M; Saji T; Harada T
    J Cardiol; 2005 Nov; 46(5):183-93. PubMed ID: 16320975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    Barst R
    Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children.
    Nakayama T; Shimada H; Takatsuki S; Hoshida H; Ishikita T; Matsuura H; Saji T
    Circ J; 2007 Nov; 71(11):1785-90. PubMed ID: 17965503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol.
    Fix OK; Bass NM; De Marco T; Merriman RB
    Liver Transpl; 2007 Jun; 13(6):875-85. PubMed ID: 17539008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.